<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04448899</url>
  </required_header>
  <id_info>
    <org_study_id>Ivabradine in CHF</org_study_id>
    <nct_id>NCT04448899</nct_id>
  </id_info>
  <brief_title>Ivabradine in Patients With Congestive Heart Failure</brief_title>
  <official_title>Effects of Ivabradine on Neopterin and NT-Pro BNP in Patients With Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the efficacy of Ivabradine therapy in patients with&#xD;
      congestive heart failure using the cardiac biomarkers NT-Pro BNP and Neopterin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy,&#xD;
           Damanhour University&#xD;
&#xD;
        -  All participants have agreed to take part in this clinical study and provide informed&#xD;
           consent&#xD;
&#xD;
        -  A 3 months, prospective interventional study.&#xD;
&#xD;
        -  Sixty ambulatory, clinically stable symptomatic patients with systolic chronic HF (≥ 4&#xD;
           weeks), on optimized standard medical therapy were consecutively included and randomly&#xD;
           allocated to the ivabradine group (n=30) and non-ivabradine group (n=30).&#xD;
&#xD;
        -  The baseline evaluation comprised physical examination, NYHA class, 12-lead&#xD;
           electrocardi¬ography (ECG), Echocardiography, blood sampling for laboratory&#xD;
           measurements, including NT-Pro BNP and Neopterin.&#xD;
&#xD;
        -  Patients in the Ivabradine group were administered Ivabradine 5 mg twice daily and doses&#xD;
           (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR&#xD;
           at rest and tolerability.&#xD;
&#xD;
        -  Patients were followed up after 1 week of initiation of ivabradine therapy then monthly&#xD;
           till the end of the study.&#xD;
&#xD;
        -  Peripheral venous blood samples were drawn between 8 and 9 am after a 30-min rest in the&#xD;
           supine position. Serum samples were frozen at -80°C until assay.&#xD;
&#xD;
        -  Levels of NT-Pro BNP and Neopterin were detected using ELISA kits as prescribed by&#xD;
           manufacturer.&#xD;
&#xD;
        -  Statistical tests appropriate to the study will be conducted to evaluate significance of&#xD;
           results&#xD;
&#xD;
        -  Results, conclusion, discussion and recommendations will be given&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">February 5, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>NT-Pro BNP</measure>
    <time_frame>three months</time_frame>
    <description>Serum BNP (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neopterin</measure>
    <time_frame>three months</time_frame>
    <description>Serum Neopterin (nmol/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Three Months</time_frame>
    <description>Heart Rate (Beat/Minute)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients administered Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability.&#xD;
Patients were followed up after 1 week of initiation of ivabradine therapy then monthly till the end of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients administered a placebo twice daily. Patients were followed up after 1 week of initiation of the study then monthly till the end of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine Oral Tablet</intervention_name>
    <description>Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability plus their standard treatment.</description>
    <arm_group_label>Ivabradine</arm_group_label>
    <other_name>Procoralan 5 mg film-coated tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blacebo plus standard treatment</intervention_name>
    <description>Blacebo plus standard treatment</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic HF, on optimized medical therapy according to European Society&#xD;
             of Cardiol¬ogy guidelines, with LV ejection fraction (LVEF) &lt; 35% according to the&#xD;
             Simpson method, New York Heart Association (NYHA) class II-III, and sinus rhythm and&#xD;
             resting HR &gt; 70/min were eligible for inclusion in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acute decompen¬sation (acute coronary syndromes and acute HF);&#xD;
&#xD;
          -  hemodynamically significant valve disease;&#xD;
&#xD;
          -  cer¬ebrovascular events during the previous 6 months;&#xD;
&#xD;
          -  dysfunctional prosthetic heart valve;&#xD;
&#xD;
          -  obstructive or non-obstructive cardiomyopathy; uncorrected congenital heart disease;&#xD;
             active myocarditis;&#xD;
&#xD;
          -  a his¬tory of resuscitation from sudden death; an absence of stable sinus rhythm,&#xD;
             severe arrhythmias; HR &lt; 60 bpm; sick sinus syndrome; second-degree and third-degree&#xD;
             atrioventricular block;&#xD;
&#xD;
          -  severe obesity (body mass index &gt; 36 kg/m²);&#xD;
&#xD;
          -  established or sus¬pected pulmonary diseases (vital capacity &lt; 80% or forced&#xD;
             expiratory volume in 1 s &lt; 80% of age spe¬cific and sex-specific reference values);&#xD;
&#xD;
          -  hemoglobin ≤ 11 g/dL;&#xD;
&#xD;
          -  treatment with non-dihydropyridine calcium-channel blockers, class I antiarrhythmic&#xD;
             agents, strong inhibitors of cytochrome P450-3A4, or QT interval-prolonging&#xD;
             medications;&#xD;
&#xD;
          -  acute and chronic kidney failure;&#xD;
&#xD;
          -  pregnancy; hypo- and hy¬perthyroidism or acute infections.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rehab Werida, Lecturer</last_name>
    <role>Study Director</role>
    <affiliation>Damanhour University, Faculty of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jayda M Dogheim, B. Pharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tanta University Hospital</name>
      <address>
        <city>Tanta</city>
        <state>El-Gharbia</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Komajda M, Tavazzi L, Francq BG, Böhm M, Borer JS, Ford I, Swedberg K; SHIFT Investigators. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail. 2015 Dec;17(12):1294-301. doi: 10.1002/ejhf.347. Epub 2015 Sep 16.</citation>
    <PMID>26377342</PMID>
  </results_reference>
  <results_reference>
    <citation>Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak M, Ford I; SHIFT Investigators. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail. 2013 Nov;15(11):1296-303. doi: 10.1093/eurjhf/hft102. Epub 2013 Jun 26.</citation>
    <PMID>23803951</PMID>
  </results_reference>
  <results_reference>
    <citation>Sasaki T, Takeishi Y, Suzuki S, Niizeki T, Kitahara T, Katoh S, Ishino M, Shishido T, Watanabe T, Kubota I. High serum level of neopterin is a risk factor of patients with heart failure. Int J Cardiol. 2010 Nov 19;145(2):318. doi: 10.1016/j.ijcard.2009.11.042. Epub 2010 Jan 6.</citation>
    <PMID>20051294</PMID>
  </results_reference>
  <results_reference>
    <citation>Richards M, Troughton RW. NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail. 2004 Mar 15;6(3):351-4. Review.</citation>
    <PMID>14987587</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 24, 2020</study_first_submitted>
  <study_first_submitted_qc>June 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2020</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Rehab Werida</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

